Canakinumab

The FDA has approved Ilaris for the treatment of gout flares in adults, marking it as the first biologic therapy to receive the nod for this indication, according to a statement from Novartis.

In this edition, germline testing ‘should be considered’ for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more.

A randomized phase 3 trial designed to evaluate canakinumab as adjuvant treatment for completely resected non-small cell lung cancer failed to meet its primary endpoint, according to the agent’s manufacturer.

Early reduction in high-sensitivity C-reactive protein is “not a good biomarker” for canakinumab’s protective impact on future gout flares, according to data published in Arthritis Care & Research.

A subset of patients with Still’s disease develop drug reactions with eosinophilia and systemic symptoms to interleukin-1 and IL-6 inhibitors, with strong associations among those with common HLA-DRB1*15 haplotypes, according to data.

The addition of canakinumab to pembrolizumab and chemotherapy failed to extend PFS or OS among patients with advanced non-small cell lung cancer, according to topline results of a randomized phase 3 trial.

Canakinumab fails to significantly increase the likelihood of survival without accompanying invasive mechanical ventilation, compared with placebo, in patients with severe COVID-19, according to data published in JAMA.

Colchicine may be considered for the secondary prevention of CV events in chronic coronary disease; however, its long-term safety remains unknown, according to a review published in the European Heart Journal.

A randomized phase 3 trial designed to evaluate canakinumab plus chemotherapy for advanced non-small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.

In a new study, interleukin-1-beta inhibition with IV canakinumab in patients hospitalized with COVID-19, myocardial injury and elevated inflammation markers did not appear to improve clinical recovery at 14 days.